Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease

Brain Research

Volumn 1230, Issue , 2008, Pages 273-280

  Miller, Miles C ^a   Tavares, Rosemarie ^a   Johanson, Conrad E ^a   Hovanesian, Virginia ^b   Donahue, John E ^a   Gonzalez, Liliana ^c   Silverberg, Gerald D ^a   Stopa, Edward G ^a  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c 3D Group for Interactive Visualization   (United States)

Author keywords

Alzheimer's disease; Blood brain barrier; Hippocampus; Microvessels; RAGE; amyloid peptide

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN[25-35];

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENDOTHELIUM CELL; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MICROVASCULATURE; PRIORITY JOURNAL; RECEPTOR BINDING;

EID: 54049094343     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.06.124     Document Type: Article

References (30)

1. Braak, H., Braak, E., 1991. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 82, 239-259.
2. Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., Del Tredici, K., 2006. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunohistochemistry. Acta Neuropathol. 112, 389-404.
3. Cirrito, J.R., Deane, R., Fagan, A.M., Spinner, M.L., Parsadanian, M., Finn, M.B., Jiang, H., Prior, J.L., Sagare, A., Bales, K.R., Paul, S.M., Zlokovic, B.V., Piwnica-Worms, D., Holtzman, D.M., 2005. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest. 115 (11), 3285-3290.
4. Deane, R., Yan, S.D., Sunmamaryan, R.K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., Zhu, H., Ghiso, J., Frangione, B., Stern, A., Schmidt, A., Armstrong, D.L., Arnold, B., Liliensiek, B., Nawroth, P., Hofman, F., Kindy, M., Stern, D., Zlokovic, B., 2003. RAGE mediates amyloid b-peptide across the blood-brain barrier and accumulation in the brain. Nat. Med. 9, 907-913.
5. Deane, R., Wu, Z., Zlokovic, B.V., 2004. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid-beta peptide clearance through transport across the blood-brain barrier. Stroke 35, 2628-2631.
6. Deane, R., Zlokovic, B.V., 2007. Role of blood brain barrier in the pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 4, 191-197.
7. Donahue, J.E., Flaherty, S.L., Johanson, C.E., Duncan III, J.A., Silverberg, J.D., Miller, M.C., Tavares, R., Yang, W., Wu, Q., Sabo, E., Hovanesian, V., Stopa, E.G., 2006. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol. (Berl.) 112, 405-415.
8. Fisman, M., 1990. Hepatic aging as an etiological factor in the development of Alzheimer's disease. Med. Hypotheses 33 (3), 163-167.
9. Haass, C., Selkoe, D.J., 2007. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112.
10. Hardy, J., 2006. A hundred years of Alzheimer's disease research. Neuron 52, 3-13.
11. Leclerc, E., Fritz, G., Weibel, M., Heizmann, C.W., Galichet, A., 2007. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J. Biol. Chem. 282, 31317-31331.
12. Masters, C.L., Multhaup, G., Simms, G., Pottgiesser, J., Martins, R.N., Beyreuther, K., 1985. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 4 (11), 2757-2763.
13. Mirra, S.S., Heyman, A., McKeel, D., Sumi, S.M., Crain, B.J., Brownlee, L.M., Vogel, F.S., Hughes, J.P., van Belle, G., Berg, L., participating CERAD neuropathologists, 1991. The consortium to establish a registry for Alzheimer's disease (CERAD): Part II. Standardization of the neuropathological assessment of Alzheimer's disease. Neurology 41, 479-486.
14. Poduslo, J., Curran, G., Sanyal, B., Selkoe, D., 1999. Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier. Neurobiol. Dis. 6 (3), 190-199.
15. Sasaki, N., Toki, S., Chowei, H., Saito, T., Nakano, N., Hayashi, Y., Takeuchi, M., Makita, Z., 2001. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res. 888 (2), 256-262.
16. Schnell, S.A., Staines, W.A., Wessendorf, M.W., 1999. Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. J. Histochem. Cytochem. 47, 719-730.
17. Selkoe, D.J., 2000. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann NY Acad. Sci. 92417-92425.
18. Silverberg, G.D., Heit, G., Huhn, S., Jaffe, R.A., Chang, S.D., Bronte-Stewart, H., Rubenstein, E., Possin, K., Saul, T.A., 2001. The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer's type. Neurology 57 (10), 1763-1766.
19. Silverberg, G.D., Mayo, M., Saul, T., Rubenstein, E., McGuire, D., 2003. Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol. 2 (8), 506-511.
20. Siman, R., Card, J.P., Nelson, R.B., Davis, L.G., 1989. Expression of beta-amyloid precursor protein in reactive astrocytes following neuronal damage. Neuron 3 (3), 275-285.
21. 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106 (12), 1489-1499.
22. Small, G.W., 1998. The pathogenesis of Alzheimer's Disease. J. Clin. Psychiatry 59 (Supplement 9), 7-14.
23. Stopa, E.G., Butala, P., Salloway, S., Johanson, C.E., Gonzalez, L., Tavares, R., Hovanesian, V., Hulette, C.M., Vitek, M.P., Cohen, R.A., 2008. Cerebral cortical arteriolar angiopathy, vascular beta-amyloid, smooth muscle actin, Braak stage, and APOE genotype. Stroke 39 (3), 814-821.
24. Trojanowski, J.Q., Clark, C.M., Schmidt, M.L., Arnold, S.E., Lee, V.M., 1997. Strategies for improving the postmortem neuropathological diagnosis of Alzheimer's disease. Neurobiol. Aging 18 (4 Suppl), S75-S79.
25. Vitek, M.P., Bhattacharya, K., Glendening, J.M., Stopa, E., Vlassara, H., Bucala, R., Manogue, K., Cerami, A., 1994. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. USA 91 (11), 4766-4770.
26. Wisniewski, T., Ghiso, J., Frangione, B., 1997. Biology of A beta amyloid in Alzheimer's disease. Neurobiol. Dis. 4, 311-328.
27. Wu, L.C., D'Amelio, F., Fox, R.A., Polyakov, I., Daunton, N.G., 1997. Light microscopic image analysis system to quantify immunoreactive terminal area apposed to nerve cells. J. Neurosci. Methods 74, 89-96.
28. Yan, S.D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., Migheli, A., Nawroth, P., Stern, D., Schmidt, A.M., 1996. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382 (6593), 685-691.
29. Zlokovic, B.V., Ghiso, J., Mackic, J.B., McComb, J.G., Weiss, M.H., Frangione, B., 1993. Blood-brain barrier transport of circulating Alzheimer's amyloid beta. Biochem. Biophys. Res. Commun. 197 (3), 1034-1040.
30. Zlokovic, B.V., 2008. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57 (2), 178-201.